Pluslife

Pluslife (普世利华) is a Chinese molecular diagnostics company founded by Professor Yangzhou Song, who serves as its founder and chief scientist . The company specializes in near-patient molecular diagnostic technology designed to empower grassroots healthcare systems , with a flagship product line centered on the MiniDock MTB Test—a palm-sized, portable tuberculosis detection platform that Qiming Venture Partners described as "first-in-class and world's first" in its category for clinical performance .

Qiming Venture Partners has been a consistent backer, participating in multiple funding rounds including a continued investment in the company's Series B in late 2025 . The firm's portfolio updates through mid-2026 track Pluslife's commercial progress: securing over $13 million in initial purchase orders to enter the Global Fund system , launching in Nigeria , and advancing into Ethiopia's national early adoption program for TB detection . In early 2026, Song was named to the TIME100 Health list for his work leading Pluslife's contributions to tuberculosis diagnostics .